Background: To evaluate the ability of QLQ-C30 in predicting mortality in community-based cancer patients in China.
Methods: A whole-cluster sampling method was adopted to enroll cancer patients in four communities in Shanghai from 2018 to 2019. The patients were surveyed using a questionnaire enquiring demographic information, cancer types, and QLQ-C30 scale. Death information of participants was collected and updated from community health care centers. Cox regression models were used to assess the relationship between various QLQ-C30 scores (i.e., total score, five dimension scores, and utility score) and all-cause mortality.
Results: A total of 3,304 participants were enrolled with a mean age of 63.9 years. Among them, 2,710 patients survived while 594 died by 2023. The mean total QLQ-C30 score in living patients was statistically significantly higher than that in deceased patients ( 92.96 vs. 85.21, p < 0.001); and the mean values of the five dimension scores and utility score were also significantly higher for the living patients. Cox regression models with the adjustment of covariates also confirmed that higher QLQ-C30 scores were associated with lower risk of death, with the hazard ratio value being 0.81 for the total score, 0.83-0.89 for the dimension scores, and 0.83 for the utility score, respectively (p < 0.001 for all).
Conclusions: QLQ-C30 could accurately predict all-cause mortality in Chinese community cancer patients.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11889892 | PMC |
http://dx.doi.org/10.1186/s12885-025-13624-z | DOI Listing |
Ann Med
December 2025
Department of Assisted Reproductive Centre, Xiangya Hospital Zhuzhou Central South University, Central South University, Zhuzhou, China.
Background: Butyrate may inhibit SARS-CoV-2 replication and affect the development of COVID-19. However, there have been no systematic comprehensive analyses of the role of butyrate metabolism-related genes (BMRGs) in COVID-19.
Methods: We performed differential expression analysis of BMRGs in the brain, liver and pancreas of COVID-19 patients and controls in GSE157852 and GSE151803.
J Cell Mol Med
March 2025
Hepatobiliary Center, the First Affiliated Hospital of Nanjing Medical University & Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, China.
The global incidence of biliary tract cancer (BTC) is on the rise, presenting a substantial healthcare challenge. The integration of immune checkpoint inhibitors (ICIs) with molecularly targeted therapies is emerging as a strategy to enhance immune responses. However, the efficacy and underlying mechanisms of these treatments in BTC are still largely unexplored.
View Article and Find Full Text PDFThorac Cancer
March 2025
Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Shandong First Medical University, Jinan, P. R. China.
Background: Robot-assisted thoracoscopic surgery (RATS) is more precise and flexible than video-assisted thoracoscopic surgery (VATS) for early-stage non-small cell lung cancer (NSCLC) treatment. This study compared the early postoperative functional recovery of patients who underwent triportal RATS with that of patients who underwent uniportal video-assisted thoracic surgery (UVATS) for segmentectomy.
Methods: This observational, prospective study included 172 patients with clinical stage I or II peripheral NSCLC who underwent RATS or UVATS segmentectomy.
Global Spine J
March 2025
Combined Neurosurgical and Orthopaedic Spine Program, University of British Columbia, Vancouver, BC, Canada.
Study DesignNarrative Review.ObjectivesTo summarize the work of the AO Spine Knowledge Forum Tumor, specifically studies from the Epidemiology, Process and Outcomes in Spine Oncology (EPOSO) study.MethodsA narrative review of all published manuscripts from the EPOSO study was undertaken.
View Article and Find Full Text PDFEur Urol
March 2025
Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. Electronic address:
Owing to the "cold" tumor immune microenvironment of prostate cancer, immune-targeting agents have shown limited efficacy in patients with advanced prostate cancer, highlighting the need for new therapies with novel mechanisms of action. In this context, T-cell engagers (TCEs), which induce T-cell-mediated killing of cancer cells by binding the CD3 receptor on T cells and a specific tumor antigen expressed on malignant cells, represent a promising therapeutic option. Multiple studies have explored the use of TCEs in previously treated patients with metastatic castration-resistant prostate cancer, and several ongoing trials are currently assessing novel TCEs either as single agents or in combinatorial regimens with molecules with a distinct mechanism of action (eg, androgen receptor pathway inhibitors and other immune-targeting agents).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!